Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis

腺癌 医学 危险系数 内科学 阶段(地层学) 病态的 肿瘤科 突变 胃肠病学 癌症 病理 生物 基因 遗传学 置信区间 古生物学
作者
Masaoki Ito,Yoshihiro Miyata,Yasuhiro Tsutani,Hiroyuki Ito,Haruhiko Nakayama,Kentaro Imai,Norihiko Ikeda,Morihito Okada
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:141: 107-113 被引量:41
标识
DOI:10.1016/j.lungcan.2020.01.018
摘要

Objectives: Recurrence risk of resected lung adenocarcinoma is represented by pathological stage (pStage), histological subtype, and potentially by EGFR mutation. However, the relationship among these factors and their combined impact on prognosis are unclear. Materials and Methods Using a multicenter database, we retrospectively investigated the prognostic impact of EGFR mutation status in relation to pStage and histological subtype in resected pN0–1M0 lung adenocarcinoma. Results Among 1155 pN0–1M0 adenocarcinoma cases, pStage 0 and IA1–IB were confirmed predominantly in EGFR-positive cases. AIS, MIA, and lepidic predominant adenocarcinoma were also more frequently found in EGFR-positive cases and showed no/little recurrence regardless of EGFR mutation status. The 5-year recurrence-free survival (RFS) of papillary, acinar, solid, and micropapillary predominant adenocarcinoma was stratified by pStage (IA1–IB, IIA–IIIA) or histological malignant subtype (intermediate or high malignant subtype), and more finely subdivided by EGFR mutation status. Positive EGFR mutation cases showed worse RFS in both classifications. Low malignant subtype and pStage IA1–IB intermediate malignant subtype showed low frequency of recurrence. Whereas, in pStage IA1–IB high malignant subtype and pStage IIA–IIIA cases, EGFR-positive cases showed poorer 5-year RFS than EGFR-negative (49.6% and 75.6%, respectively, hazard ratio [HR] = 1.84, 95% CI = 1.38–7.42, p < 0.01) and multivariate analysis indicated positive EGFR mutation status was significantly related to poorer PRF (HR = 2.005, 95% CI = 1.029–3.906, p = 0.041). Conclusion EGFR mutation harbored primarily in early-stage or low-malignant histological subtypes with no/little recurrence. In pN0–1M0 adenocarcinoma with higher risk of recurrence, positive EGFR mutation cases showed worse RFS. EGFR mutation status enables better stratification of recurrence risk when considering pStage and histological malignant subtype.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
顾矜应助GS11采纳,获得10
2秒前
SuperZzz完成签到,获得积分10
2秒前
李大伟发布了新的文献求助10
4秒前
贾克斯完成签到,获得积分20
4秒前
闾丘剑封发布了新的文献求助10
4秒前
量子星尘发布了新的文献求助30
4秒前
李健应助hanleiharry1采纳,获得10
4秒前
5秒前
科研通AI2S应助Hey采纳,获得20
7秒前
爱笑若冰完成签到,获得积分10
7秒前
tomorrow完成签到 ,获得积分10
8秒前
9秒前
Rei完成签到 ,获得积分20
10秒前
科研通AI2S应助无所谓的啦采纳,获得10
10秒前
田様应助打我呀采纳,获得10
10秒前
11秒前
11秒前
科研狗发布了新的文献求助10
11秒前
yixiaolou发布了新的文献求助10
12秒前
李大伟完成签到,获得积分10
13秒前
慎独完成签到,获得积分10
13秒前
MchemG应助科研通管家采纳,获得10
14秒前
乐乐应助科研通管家采纳,获得10
14秒前
orixero应助科研通管家采纳,获得30
14秒前
SYLH应助科研通管家采纳,获得30
14秒前
CHENG_2025应助科研通管家采纳,获得10
14秒前
小萌发布了新的文献求助10
14秒前
14秒前
Jasper应助科研通管家采纳,获得10
14秒前
在水一方应助科研通管家采纳,获得30
14秒前
SYLH应助科研通管家采纳,获得10
14秒前
爆米花应助科研通管家采纳,获得10
14秒前
英姑应助科研通管家采纳,获得10
15秒前
传奇3应助科研通管家采纳,获得10
15秒前
撸撸大仙发布了新的文献求助10
15秒前
MchemG应助科研通管家采纳,获得10
15秒前
MchemG应助科研通管家采纳,获得10
15秒前
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174